Menu Close

Pregnancy Outcomes in the Omalizumab Pregnancy Registry and a Disease-Matched Comparator Cohort

Citation

Namazy, Jennifer A.; Blais, Lucie; Andrews, Elizabeth B.; Scheuerle, Angela E.; Cabana, Michael D.; Thorp, John M., Jr.; Umetsu, Dale T.; Veith, Joachim H.; Sun, Diana; & Kaufman, Derrick G., et al. (2020). Pregnancy Outcomes in the Omalizumab Pregnancy Registry and a Disease-Matched Comparator Cohort. Journal of Allergy and Clinical Immunology, 145(2), 528-36.e1.

Abstract

Background: The Observational Study of the Use and Safety of Xolair (omalizumab) during Pregnancy (EXPECT) pregnancy registry was a prospective observational study established in 2006 to evaluate perinatal outcomes in pregnant women exposed to omalizumab and their infants.

URL

https://doi.org/10.1016/j.jaci.2019.05.019

Reference Type

Journal Article

Journal Title

Journal of Allergy and Clinical Immunology

Author(s)

Namazy, Jennifer A.
Blais, Lucie
Andrews, Elizabeth B.
Scheuerle, Angela E.
Cabana, Michael D.
Thorp, John M., Jr.
Umetsu, Dale T.
Veith, Joachim H.
Sun, Diana
Kaufman, Derrick G.
Covington, Deborah L.
Mukhopadhyay, Santanu
Fogel, Robert B.
Lopez-Leon, Sandra
Spain, C. Victor

Year Published

2020

Volume Number

145

Issue Number

2

Pages

528-36.e1

Reference ID

13009